Gavins Felicity - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Gavins Felicity's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Gavins Felicity
Verified
Senior Writer, BioPharmaJournal.com
Beats
Science , Engineering , Technology , Health
Politics—for now
Content
By Gavins Felicity| BioPharmaJournal.com@ News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More. Senti Biosciences, Inc. (Nasdaq: SNTI), a trailblazer in the biotechnology industry, has recently grabbed headlines with its remarkable stock performance and innovative financial strategies.
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310%
By Gavins Felicity| BioPharmaJournal.com@ News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More. HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company based in Miramar, Florida, made headlines on November 18, 2024, with a remarkable 310.73% surge in its stock price, closing at $1.24.
By Gavins Felicity| BioPharmaJournal.com@ News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More. Senti Biosciences, Inc. (Nasdaq: SNTI), a trailblazer in the biotechnology industry, has recently grabbed headlines with its remarkable stock performance and innovative financial strategies.
Company Info
BioPharmaJournal.com